April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Long-term Efficacy Of Combined Endoscopic Cyclophotocoagulation (ECP) And Phacoemulsification In The Treatment Of Mild-moderate Glaucoma
Author Affiliations & Notes
  • Omar S. Faridi
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan
  • Michael J. Siegel
    Kresge Eye Institute, Wayne State University, Detroit, Michigan
  • Chirag K. Gupta
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan
  • Joseph C. Neilitz
    Ophthalmology, St. John Providence Hospital-Michigan State University, Madison Heights, Michigan
  • Matthew E. Citron
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan
    Glaucoma, Glaucoma Center of Michigan, Southfield, Michigan
  • Marc J. Siegel
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan
    Glaucoma, Glaucoma Center of Michigan, Southfield, Michigan
  • Les I. Siegel
    Ophthalmology, William Beaumont Hospital, Royal Oak, Michigan
    Glaucoma, Glaucoma Center of Michigan, Southfield, Michigan
  • Footnotes
    Commercial Relationships  Omar S. Faridi, None; Michael J. Siegel, None; Chirag K. Gupta, None; Joseph C. Neilitz, None; Matthew E. Citron, None; Marc J. Siegel, None; Les I. Siegel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2633. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Omar S. Faridi, Michael J. Siegel, Chirag K. Gupta, Joseph C. Neilitz, Matthew E. Citron, Marc J. Siegel, Les I. Siegel; The Long-term Efficacy Of Combined Endoscopic Cyclophotocoagulation (ECP) And Phacoemulsification In The Treatment Of Mild-moderate Glaucoma. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2633.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long-term efficacy of combined endoscopic cyclophotocoagulation (ECP) and phacoemulsification in the treatment of mild-moderate glaucoma.

Methods: : Retrospective non-comparative non-industry sponsored interventional case series at one center with procedures performed by three glaucoma trained surgeons from 2004-2007. Patients were excluded if they had severe glaucoma or had prior phacoemulsification, cyclodestructive, filtering, or tube-shunt procedures. Utilizing IOP, glaucoma medication use, and complications as main outcome measures, evaluation was performed from baseline up to 66 months. Bonferroni’s adjustment was made for the multiple comparisons performed to baseline IOP.

Results: : The mean baseline IOP in 187 eyes of 111 patients was 17.69 ± 0.35 (SE) mmHg (range 8.0-45.00; median 17.00), 15.18 ± 0.43 at month 12 (n=157; P <0.0001), 15.06 ± 0.32 at month 24 (n=157; P <0.0001), 14.81 ± 0.29 at month 36 (n=132; P <0.0001), 14.94 ± 0.41 at month 48 (n=52; P=0.012), 13.93 ± 0.6 at month 54 (n=30; P=0.005), 14.87 ± 0.52 at month 60 (n=15; P=1.000). The baseline mean number of glaucoma medications was 0.87 ± 0.04 (SE) (median 1.00; range 0-3) and 0.33 ± 0.17 at month 60. The mean IOP significantly changes with an average reduction of 14.57% ± 1.78. The likelihood of sustained IOP control without the use of glaucoma medications is significant at every time point showing that patients were 7.78 times as likely to have no glaucoma medications at 12 months, 8.07 at 24 months, 8.45 at 36 months, 21.37 at 48 months, and 65.42 times more likely to be without glaucoma medications at 60 months (all P<0.0001). Subsequent secondary glaucoma procedures were performed in 9 patients, including 7 selective laser trabeculoplasties, 2 laser peripheral iridotomies, 2 trabeculectomies, 1 tube shunt, and 1 diode laser. Cystoid macular edema occurred in 3 patients, successfully treated in 2 patients with one lost to follow-up. One patient required a penetrating keratoplasty.

Conclusions: : The use of ECP and phacoemulsification in mild-moderate glaucoma safely and effectively lowers IOP and the dependence on glaucoma medications up to five years. This combination procedure may in turn lead to less financial burden and adverse effects associated with glaucoma drops.

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: outcomes/complications • ciliary processes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×